DR-344 The role of T-cell associated chemokines in shaping the tumor immune interphase and for the initiation of effective anti-tumor immune responses in advanced skin cancers in the course of tumor progression
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-344 The role of T-cell associated chemokines in shaping the tumor immune interphase and for the initiation of effective anti-tumor immune responses in advanced skin cancers in the course of tumor progression
T cell based immunotherapies have significantly advanced the treatment of advanced skin cancers and malignant melanoma in particular. However, initial …
DR-310 Clinical actionability for and heritable factors involved in glioblastoma
This project aims to use whole genome sequencing data to 1) describe the driver landscape of glioblastoma, 2) determine potential …
DR-336 Genomic signatures of cancer therapies
Cancer is a disease characterized by genomic alterations, including mutations, copy number variations, and structural variants. These genomic alterations can …
DR-305 ctDNA analysis to monitor response to neoadjuvant chemoradiation in esohageal cancer patients
After neoadjuvant treatment of esophageal cancer, the standard treatment is resection. However, in circa 20% of patients, no vital tumor …
DR-279 Identification and validation of genomic and transcriptomic based biomarkers for organoid and patient response in a large colorectal cancer cohort
With this project, we aim to personalize cancer treatment and find new treatments for cancer sub-types by investigating the (expression …
DR-340 Discovering novel noncoding cancer drivers using genomic conformation and context models
Cancer cells are characterized by the accumulation of genetic mutations, only few of which are needed to trigger the malignancy. …
DR-325 Deciphering the role of Trem1 signaling in breast cancer metastasis
Trem1 is an LPS dimerizing receptor that is mainly involved in bacterial and danger-damage-associated signals. Yet, its role in cancer …
DR-332 Transcriptional evolution of lung cancer during progression and metastasis
Metastasis is the endpoint of tumorigenesis and is generally diagnosed at an untreatable stage. The molecular mechanisms underlying metastasis and …
DR-342 Telomere fusions in metastatic tumors
Telomeres protect our genomesfrom deterioration and instability. A key aspect of telomere biology is the occurrence of telomere fusions, which …
DR-316 Evaluating therapeutic efficacy of ERBB TKIs on patients harboring ERBB alterations
The EGFR family of receptor tyrosine kinases are frequently mutated (2-30% of cases in various cancers). Recently, samples harboring co-occurring …
DR-324 Identification of non-coding aberrations that drive cancer
The aim of this project is to perform pan-cancer and cancer-type specific analyses to gain insight into molecular aetiology, molecular …
DR-287 Comparing metastatic and primary breast tumours through the lens of integrated subtypes
Under DR-129, we have generated preliminary data that shows differences in the distribution of our genomic breast cancer subtypes between …
Gepersonaliseerde selectie van experimentele behandeling bij patiënten met gevorderde solide kanker is mogelijk met behulp van whole genome sequencing.